B
Bishal Gyawali
Researcher at Queen's University
Publications - 261
Citations - 16176
Bishal Gyawali is an academic researcher from Queen's University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 25, co-authored 194 publications receiving 10845 citations. Previous affiliations of Bishal Gyawali include State University of New York System & Kathmandu.
Papers
More filters
Journal ArticleDOI
Cardio-metabolic disease risk factors among South Asian labour migrants to the Middle East: a scoping review and policy analysis
Shiva Raj Mishra,Saruna Ghimire,Chandni Joshi,Bishal Gyawali,Archana Shrestha,Dinesh Neupane,Sudesh Raj Sharma,Yashashwi Pokharel,Salim S. Virani,Salim S. Virani +9 more
TL;DR: A high burden of cardio-metabolic risk factors among the migrants as well as among the populations in the home and the host countries is found, and the lack of specific focus on screening during different stages of labor migration should receive attention.
Journal ArticleDOI
Cheaper Options in the Prevention of Chemotherapy-Induced Nausea and Vomiting
TL;DR: This is the first work, to the authors' knowledge, to review specifically the less expensive alternatives in CINV prevention, which is particularly important for those working in resource-limited settings.
Journal ArticleDOI
Ischemic Stroke and Impact of Thyroid Profile at Presentation: A Systematic Review and Meta-analysis of Observational Studies.
Rashmi Dhital,Dilli Ram Poudel,Niranjan Tachamo,Bishal Gyawali,Sijan Basnet,Pragya Shrestha,Paras Karmacharya +6 more
TL;DR: Elevated initial TSH (clinical or subclinical hypothyroidism) may correspond to better functional outcomes, whereas low initial T3/fT3 might correlate with worse outcomes in acute ischemic stroke among clinically euthyroid patients.
Journal ArticleDOI
Drugs that lack single-agent activity: are they worth pursuing in combination?
Bishal Gyawali,Vinay Prasad +1 more
TL;DR: Whether these anticancer drugs provide any tangible clinical benefits and are worthy of continued development, or whether R&D efforts would be better focused elsewhere, is examined.
Journal ArticleDOI
Response Rates and Durations of Response for Biomarker-Based Cancer Drugs in Nonrandomized Versus Randomized Trials.
TL;DR: Caution must be exercised when approving or prescribing targeted drugs based on data on durable responses derived from non-RCTs, because the responses could be overestimates and poor predictors of survival benefit.